3 Promising Penny Stocks On US Exchanges With Over $600M Market Cap

Major U.S. stock indexes opened slightly lower as investors brace for a significant week of earnings reports, with the Dow Jones, S&P 500, and Nasdaq Composite each experiencing minor declines. Despite the cautious start to the week, opportunities still abound for those looking beyond the high-profile stocks dominating headlines. Though 'penny stocks' might seem like a term from another era, they continue to offer potential value; these smaller or newer companies can provide affordability and growth prospects when backed by strong financials.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.7987	$5.8M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$2.95	$485.02M	★★★★★★
RLX Technology (NYSE:RLX)	$1.65	$2.1B	★★★★★★
ARC Document Solutions (NYSE:ARC)	$3.42	$147.91M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.595	$52.63M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$3.76	$114.05M	★★★★★★
MIND C.T.I (NasdaqGM:MNDO)	$1.88	$39.56M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$1.07	$96.23M	★★★★★☆

Click here to see the full list of 749 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

AbCellera Biologics (NasdaqGS:ABCL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AbCellera Biologics Inc. operates as a company focused on antibody drug discovery and development, with a market cap of approximately $845.69 million.

Operations: The company generates revenue primarily from its Discovery and Development of Antibodies segment, amounting to $33.05 million.

Market Cap: $845.69M

AbCellera Biologics Inc., with a market cap of US$845.69 million, focuses on antibody drug discovery and development. Despite being unprofitable, the company has no debt, and its short-term assets significantly exceed liabilities. Recent earnings show declining revenue at US$7.32 million for Q2 2024 compared to US$10.06 million a year earlier, with net losses widening to US$36.93 million from US$30.53 million. Notably, AbCellera expanded its collaboration with Eli Lilly for therapeutic antibodies in various fields, securing upfront payments and potential future royalties—highlighting strategic partnerships as a key growth avenue amidst financial challenges.

• Get an in-depth perspective on AbCellera Biologics' performance by reading our balance sheet health report here.
• Gain insights into AbCellera Biologics' future direction by reviewing our growth report.

Taboola.com (NasdaqGS:TBLA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taboola.com Ltd. operates an artificial intelligence-based algorithmic engine platform across various countries including Israel, the United States, the United Kingdom, and Germany, with a market cap of approximately $1.23 billion.

Operations: The company generates revenue of $1.62 billion from its advertising segment.

Market Cap: $1.23B

Taboola.com Ltd., with a market cap of US$1.23 billion, operates in the advertising sector, generating US$1.62 billion in revenue. Despite being unprofitable, Taboola has managed to reduce its net losses significantly and maintains more cash than debt, providing a stable financial footing. Recent innovations include Abby and Maximize Conversions—AI-driven tools enhancing advertiser efficiency and campaign effectiveness—which have seen substantial adoption among advertisers like Hyundai and Peugeot Turkey. The company's strategic advancements align with industry trends towards AI integration, positioning it well for potential growth despite current profitability challenges.

• Unlock comprehensive insights into our analysis of Taboola.com stock in this financial health report.
• Assess Taboola.com's future earnings estimates with our detailed growth reports.

Elite Pharmaceuticals (OTCPK:ELTP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals, with a market cap of approximately $624.94 million.

Operations: The company generates revenue primarily from its Abbreviated New Drug Applications (ANDA) segment, which accounts for $66.45 million.

Market Cap: $624.94M

Elite Pharmaceuticals, Inc. has demonstrated significant growth, with first-quarter revenue reaching US$18.8 million, up from US$8.98 million the previous year. Despite this increase, net income decreased to US$0.62 million from US$1.14 million a year ago, indicating potential profitability challenges amidst rising revenues. The company's financial health is supported by more cash than total debt and short-term assets exceeding liabilities, which provides a cushion against volatility and market fluctuations often associated with penny stocks. However, shareholder dilution over the past year suggests potential concerns regarding equity value preservation for investors in the long term.

• Click to explore a detailed breakdown of our findings in Elite Pharmaceuticals' financial health report.
• Learn about Elite Pharmaceuticals' historical performance here.

Turning Ideas Into Actions

• Get an in-depth perspective on all 749 US Penny Stocks by using our screener here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com